Active ingredient : Bortezomib Bortezomib
VELCADE is a prescription medication used in the treatment of multiple myeloma and certain types of lymphoma. It contains the active ingredient Bortezomib, which belongs to a class of drugs known as proteasome inhibitors. By blocking the action of the proteasome, VELCADE disrupts the cell cycle of cancer cells, leading to their death and helping to reduce tumor size.
Couldn't load pickup availability
Free shipping and returns available on all orders!
We ship all US domestic orders within 5-10 business days
VELCADE (Bortezomib) is a prescription medication used for the treatment of multiple myeloma and certain types of lymphoma. It works as a proteasome inhibitor, disrupting the cell cycle and leading to cancer cell death.
The usual starting dose of VELCADE is 1.3 mg/m², administered as an injection into the bloodstream. It is typically given twice a week for two weeks, followed by a rest period. Dosage may vary based on individual patient needs and response to treatment.
Common side effects may include:
Consult your healthcare provider for a complete list of side effects and any serious reactions.
Inform your doctor about any allergies, current medications, and your complete medical history, especially if you have kidney problems or a history of nerve damage.
Yes, VELCADE is often used in combination with other chemotherapy agents. Your healthcare provider will determine the best treatment plan for you.
VELCADE is administered as an injection, either intravenously or subcutaneously, as directed by your healthcare provider.